OPRX
OptimizeRx Corporation
OPRX has the edge over UNH overall, supported by stronger fundamentals and stronger valuation.
UNH
UnitedHealth Group Incorporated
UNH has lower modeled downside risk, despite its lower overall score.
OPRX Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Healthy | |
| Strong | |
| Strong |
OPRX's profitability, cash flow and balance sheet are currently healthy, but its revenue is under pressure.
UNH Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Healthy | |
| Healthy |
UNH's cash flow and balance sheet are currently healthy, and its revenue and profitability are stable.
OPRX PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 9.2x | $8.87 | — |
| Cheap | 20x | $4.88 | -45% |
| Current | 37x | $8.87 | — |
| Fair | 592x | $142 | +1503% |
| Expensive | 1,627x | $391 | +4303% |
Historical ranges are pointers, not guarantees.
OPRX's PE is in its fair range at 37x. If earnings grow as analysts expect, today's price would be 9.2x next year's earnings, in its cheap range.
UNH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 18x | $405 | — |
| Cheap | 19x | $325 | -20% |
| Fair | 23x | $410 | +1.2% |
| Current | 23x | $405 | — |
| Expensive | 30x | $526 | +30% |
Historical ranges are pointers, not guarantees.
UNH has the edge over OPRX in the historical PE scenario, which offers more potential upside but is not a forecast.
OPRX Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Growth | |
| Strongly improving | |
| Limited | |
| Moderate |
OPRX has the edge over UNH on the outlook, with more favorable revenue expectations.
UNH Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Stable | |
| Improving | |
| Moderate | |
| Low |
Analysts expect UNH's earnings to grow and its profitability to improve, with its revenue holding steady. However, they disagree widely on these estimates.
OPRX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.97 | +304% |
| Q2 2026 | $0.24 | +$0.78 |
| Q1 2026 | $0.36 | +$1.20 |
| Q4 2025 | $0.27 | +$1.37 |
| Q3 2025 | $0.00 | +$1.35 |
| Q2 2025 | -$0.54 | +$0.48 |
| Q1 2025 | -$0.84 | +$0.20 |
| Q4 2024 | -$1.10 | -$0.07 |
| Q3 2024 | -$1.35 | -$0.54 |
OPRX has the edge over UNH on earnings, with more consistent year-over-year improvement.
UNH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $22.65 | +29% |
| Q3 2026 | $17.55 | -8.5% |
| Q2 2026 | $15.58 | -33% |
| Q1 2026 | $13.28 | -44% |
| Q4 2025 | $13.23 | -15% |
| Q3 2025 | $19.17 | +25% |
| Q2 2025 | $23.09 | +53% |
| Q1 2025 | $23.89 | +46% |
| Q4 2024 | $15.51 | -35% |
UNH's earnings per share have fallen from their peak: $17.55 over the past year, against $23.89 in early 2025.
OPRX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $20.5M | -30% |
| Q1 2026 | $19.8M | -9.5% |
| Q4 2025 | $32.2M | -0.2% |
| Q3 2025 | $26.1M | +22% |
| Q2 2025 | $29.2M | +2307% |
| Q1 2025 | $21.9M | +1168770% |
| Q4 2024 | $32.3M | +14% |
| Q3 2024 | $21.3M | +30% |
OPRX's revenue has slid since its 2024 peak: $21M last quarter, down 30% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -0.4% | -11 points |
| Q1 2026 | 2% | +12 points |
| Q4 2025 | 27% | +15 points |
| Q3 2025 | 7.9% | +48 points |
| Q2 2025 | 11% | +320 points |
| Q1 2025 | -9.6% | +268061 points |
| Q4 2024 | 11% | +50 points |
| Q3 2024 | -40% | -18 points |
OPRX's operating margin was −0.4% last quarter, down 11 points from the same quarter a year ago.
UNH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $112.7B | -0.4% |
| Q2 2026 | $112B | +0.4% |
| Q1 2026 | $111.7B | +2% |
| Q4 2025 | $113.2B | +12% |
| Q3 2025 | $113.2B | +12% |
| Q2 2025 | $111.6B | +13% |
| Q1 2025 | $109.6B | +9.8% |
| Q4 2024 | $100.8B | +6.8% |
UNH's revenue has held roughly level: $113B last quarter, about level with the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 5.8% | +2 points |
| Q2 2026 | 7.1% | +2.5 points |
| Q1 2026 | 8.1% | -0.3 points |
| Q4 2025 | 0.3% | -7.4 points |
| Q3 2025 | 3.8% | -4.8 points |
| Q2 2025 | 4.6% | -3.4 points |
| Q1 2025 | 8.3% | +0.4 points |
| Q4 2024 | 7.7% | -0.4 points |
UNH has the edge over OPRX on profitability, with a higher operating margin.
OPRX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $8.6M | +88% |
| Q1 2026 | -$488K | -113% |
| Q4 2025 | $7.1M | +3810% |
| Q3 2025 | $3.2M | +80% |
| Q2 2025 | $4.6M | +518% |
| Q1 2025 | $3.8M | +84% |
| Q4 2024 | $181K | +$6.4M |
| Q3 2024 | $1.8M | +23% |
OPRX has the edge over UNH on cash flow, with more consistent year-over-year improvement.
UNH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $4.3B | -16% |
| Q2 2026 | $10.3B | +63% |
| Q1 2026 | $8.1B | +79% |
| Q4 2025 | $160M | -89% |
| Q3 2025 | $5.1B | -61% |
| Q2 2025 | $6.3B | +6.9% |
| Q1 2025 | $4.6B | +1037% |
| Q4 2024 | $1.5B | +$7.6B |
UNH still generates free cash flow, though less than at its 2022 peak: $22.8B over the past year.
OPRX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.1% | +24K shares |
| 1 year | -1.2% | -230K shares |
| 3 years | +11% | +1.8M shares |
| 5 years | +3.8% | +681K shares |
| Available history | +33% | +4.6M shares |
OPRX has the edge over UNH on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2023 | — |
| Q2 2023 | $7.5M |
| Q4 2022 | $7.5M |
| Q3 2022 | $12.2M |
UNH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.4% | -4M shares |
| 1 year | -0.7% | -6M shares |
| 3 years | -3.6% | -34M shares |
| 5 years | -5.5% | -53M shares |
| Available history | -6.6% | -64M shares |
UNH has 902M diluted shares, down 0.7% from a year ago, with $5B in buybacks over the past year.
| Quarter | Spent |
|---|---|
| Q3 2026 | $3.4B |
| Q2 2026 | $1.6B |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | $2.5B |
| Q1 2025 | $3B |
| Q4 2024 | $5B |
UNH spent $5B buying back its own shares over the past year, down 52% from the year before.
OPRX Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | -0.3x | Net Cash |
| Q1 2026 | 0.2x | Very low |
| Q4 2025 | 0.1x | Very low |
| Q3 2025 | 0.8x | Very low |
| Q2 2025 | 23.5x | High |
OPRX has the edge over UNH on leverage, with a lower net debt burden relative to earnings.
UNH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.7x | Healthy |
| Q2 2026 | 1.7x | Healthy |
| Q1 2026 | 2.2x | Moderate |
| Q4 2025 | 2.3x | Moderate |
| Q3 2025 | 1.7x | Healthy |
| Q2 2025 | 1.5x | Healthy |
| Q1 2025 | 1.3x | Healthy |
| Q4 2024 | 1.4x | Healthy |
UNH's net debt is about 1.7 years of its operating earnings (EBITDA), about the same as a year ago.
OPRX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 57.0 | Neutral |
| Stochastic | 77.6 | Neutral |
OPRX's weekly RSI is 57 (neutral) and its Stochastic is 78 (neutral).
UNH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 56.4 | Neutral |
| Stochastic | 60.0 | Neutral |
UNH's weekly RSI is 56 (neutral) and its Stochastic is 60 (neutral).
OPRX PE vs Healthcare Sector
| Metric | OPRX | Sector median | Relative |
|---|---|---|---|
| PE | 37x | 26x | 43% above |
| PE % | 45 | 29 | 16 pts above |
OPRX is trading at 37x earnings, a 43% premium to the Healthcare sector's median of 26x.
UNH PE vs Healthcare Sector
| Metric | UNH | Sector median | Relative |
|---|---|---|---|
| PE | 23x | 26x | 11% below |
| PE % | 47 | 29 | 18 pts above |
UNH has the edge over OPRX on valuation relative to its sector.
OPRX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $8.69 | 2.1% above |
| 20 week MA | $7.75 | 14% above |
| 50 week MA | $8.11 | 9.4% above |
| 100 week MA | $10.1 | 12% below |
| 200 week MA | $10.7 | 17% below |
OPRX has bounced recently, but its long-term trend is still down: it's above its 8-, 20- and 50-week averages, but 17% below its 200-week average.
UNH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $394.2 | 2.8% above |
| 20 week MA | $400.5 | 1.2% above |
| 50 week MA | $361.2 | 12% above |
| 100 week MA | $376.0 | 7.8% above |
| 200 week MA | $446.6 | 9.3% below |
UNH has the edge over OPRX on trend strength, trading above more of its moving averages.
OPRX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $10.1 | $31.6 | +214% |
| 2021 | $31.6 | $60.5 | +92% |
| 2022 | $60.5 | $16.7 | -72% |
| 2023 | $16.7 | $14.3 | -14% |
| 2024 | $14.3 | $5.09 | -64% |
| 2025 | $5.09 | $12.5 | +145% |
| 2026 YTD | $12.5 | $8.87 | -29% |
OPRX's yearly returns have swung widely, from +214% in 2020 to −72% in 2022. It's down 29% so far in 2026.
UNH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $296.0 | $340.8 | +15% |
| 2021 | $340.8 | $495.4 | +45% |
| 2022 | $495.4 | $531.3 | +7.3% |
| 2023 | $531.3 | $526.5 | -0.9% |
| 2024 | $526.5 | $510.0 | -3.1% |
| 2025 | $510.0 | $331.8 | -35% |
| 2026 YTD | $331.8 | $405.1 | +22% |
UNH has the edge over OPRX on returns for 2026, with the stronger performance.